(Reuters) – The European health regulator said on Monday it had received an application from U.S. drugmaker Gilead Sciences Inc for approval of its antiviral drug, remdesivir, as a potential COVID-19 treatment in Europe.
“The assessment of the benefits and risks of remdesivir is being performed under a reduced timeline and an opinion could be issued within weeks,” the European Medicines Agency said in its statement. (https://bit.ly/2Yg8siD)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M.)
